Featured Research

from universities, journals, and other organizations

Two drugs for treating type 1 diabetes compared

Date:
July 3, 2014
Source:
Sanford Health
Summary:
Participants between the ages of 11 and 36 received either the two drugs or a placebo while continuing their insulin injections. The group receiving the drugs did not experience an improvement in insulin production, but some study participants whose GLP-1 and gastrin levels increased may have better preserved beta cell levels.

The results of The Sanford Project's first clinical trial are published in the July edition of The Lancet Diabetes & Endocrinology, revealing the outcome of a two-year study exploring the benefits of two drugs in treating type 1 diabetes.

The study is titled "Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial."

In August 2012, The Sanford Project Todd and Linda Broin Chair Alex Rabinovitch, M.D., and his team announced they had reached full patient enrollment for Restore Pancreatic Insulin Response in type 1 diabetes (REPAIR-T1D). Based on a successful mouse model, the study explored if two FDA-approved drugs, sitagliptin and lansoprazole, could regenerate beta cells in humans by improving levels of GLP-1 and gastrin hormones. Type 1 diabetics experience a loss of insulin-producing beta cells and need to inject insulin into their bodies manually.

Sixty-nine participants between the ages of 11 and 36 received either the two drugs or a placebo while continuing their insulin injections. The group receiving the drugs did not experience an improvement in insulin production, but some study participants whose GLP-1 and gastrin levels increased may have better preserved beta cell levels.

"While the results of our first clinical trial did not indicate a regeneration of beta cells as a result of the drugs used, it is promising that some of the participants seemed to have preserved beta cells that may have otherwise died," said Rabinovitch. "The next step is to design another study based on what we learned from the REPAIR trial and continue to make progress towards a cure."

Rabinovitch is finalizing plans for the next clinical trial involving participants from the REPAIR-TID project to better understand why responses to the sitagliptin and lansoprazole differed among participants.

"What is perhaps most remarkable about the completion of this trial is the pace in which we are able to conduct research here at Sanford because of our size and strategic investments in people and infrastructure," said David Pearce, Ph.D., vice president and chief operating officer for Sanford Research. "The results have left The Sanford Project team both anxious and prepared to learn more about why patients reacted differently to the two drugs that were utilized in this clinical trial."

The REPAIR-T1D trial was funded by Sanford Research and JDRF.

"Curing T1D is challenging because of the complexity of the disease and the differences among the people who are diagnosed with it" said JDRF director and program lead Patricia Kilian, Ph.D. "The REPAIR-T1D study was an important translational effort; testing what was a promising approach in animals in a well-executed study with people. The results represent another step on the path towards improving beta cell function for people with T1D and our ultimate goal of finding a cure for the disease."


Story Source:

The above story is based on materials provided by Sanford Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kurt J Griffin, Paul A Thompson, Michael Gottschalk, Jennifer H Kyllo, Alex Rabinovitch. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology, 2014; DOI: 10.1016/S2213-8587(14)70115-9

Cite This Page:

Sanford Health. "Two drugs for treating type 1 diabetes compared." ScienceDaily. ScienceDaily, 3 July 2014. <www.sciencedaily.com/releases/2014/07/140703142158.htm>.
Sanford Health. (2014, July 3). Two drugs for treating type 1 diabetes compared. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/07/140703142158.htm
Sanford Health. "Two drugs for treating type 1 diabetes compared." ScienceDaily. www.sciencedaily.com/releases/2014/07/140703142158.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins